Related Experiment Video
Updated: Jan 19, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Expression and clinical significance of CPS1 in glioblastoma multiforme
Geting Wu1, Yuanliang Yan2, Yangying Zhou3
1Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Abstract:
Carbamoyl phosphate synthetase-1 (CPS1), the first rate-limiting mitochondrial enzyme in the urea cycle, regulates proliferation and differentiation during tumor progression. However, the detailed function of CPS1 in glioblastoma Multiforme (GBM) is still unclear. Here, we highlight mechanisms for CPS1 upregulation and the effects of upregulated CPS1 on GBM tumorigenesis. The transcriptome data from several public databases, such as Oncomine and GEPIA, revealed that CPS1 transcriptional level was significantly upregulated in GBM tissues and cells. Moreover, CPS1 was hypomethylated in GBM tissues. The Wanderer database, linked to the Cancer Genome Atlas (TCGA), showed the association between CPS1 expression or its methylation values and the clinicopathological parameters in GBM patients. Our work fully demonstrated that CPS1 expression was upregulated in GBM and this gene could be used as a potential diagnostic and prognosis indicator for GBM.
Related Concept Videos
09:02Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
07:37Translational Orthotopic Models of Glioblastoma Multiforme
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
09:07Sonodynamic Therapy for the Treatment of Glioblastoma Multiforme in a Mouse Model Using a Portable Benchtop Focused Ultrasound System
08:00The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Intravenous Administration of Therapeutic Nanoparticles in a Murine Glioblastoma Model

